1. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy

   Creutzberg, C. L., Leon-Castillo, A., de Boer, S. M., Powell, M. E., Mileshkin, L. R., Mackay, H. J., Leary, A., Nijman, H. W., Singh, N., Pollock, P., Fyles, A., Haie-Meder, C., Smit, V. T. H. B. M., Edmondson, R. J., Putter, H., Kitchener, H. C., Crosbie, E. J., de Bruyn, M., Nout, R. & Bosse, T., Oct-2019, In : Annals of Oncology. 30, p. 899-+ 2 p.

   Research output: Contribution to journal › Meeting Abstract › Academic

2. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial

   CARMELINA Investigators, 1-Jan-2019, In : JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 321, 1, p. 69-79 11 p.

   Research output: Contribution to journal › Article › Academic › peer-review

3. Patterns of recurrence in the randomised PORTEC-3 trial of chemoradiotherapy for endometrial cancer

   De Boer, S. M., Powell, M. E., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P. B., Ledermann, J. A., Khaw, P., Colombo, A., Fyles, A., Baron, M. H., Jurgenliemk-Schulz, I. M., Kitchener, H. C., Nijman, H. W., Wilson, G., Kolodziej, I., Carinelli, S., Lutgens, L. C. H. W., Smit, V. T. H. B. M., Singh, N., Nout, R. A., Verhoeven-Adema, K. W., Putter, H. & Creutzberg, C. L., Apr-2018, In : Radiotherapy and Oncology. 127, p. S171-S172 2 p.

   Research output: Contribution to journal › Meeting Abstract › Academic

4. Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer

   PORTEC Study Grp, Feb-2018, In : Annals of Oncology. 29, 2, p. 424-430 7 p.

   Research output: Contribution to journal › Article › Academic › peer-review

View all (4) »